Spectral AI, Inc. (MDAI) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Spectral AI, Inc. is an artificial intelligence company focused on predictive medical diagnostics, specifically its DeepView System for burn wound assessment. On May 26, 2026, the FDA granted De Novo classification for the DeepView System, authorizing commercial distribution in the United States. The company currently generates revenue primarily from government research and development contracts, notably with the Biomedical Advanced Research and Development Authority (BARDA), and has not yet generated product revenue.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $3.52 million | $7.52 million | $11.77 million |
| Gross Profit | $1.11 million | $3.14 million | $5.46 million |
| Gross Margin | 31.6% | 41.8% | 46.4% |
| Operating Loss | $(4.32) million | $(6.30) million | $(3.02) million |
| Net Loss | $(4.18) million | $(7.59) million | $(5.07) million |
| Cash and Equivalents | $13.98 million (as of June 30, 2026) | N/A | |
| Total Debt Outstanding | $14.9 million (as of June 30, 2026) | N/A | |
| Warrant Liabilities | $11.78 million (as of June 30, 2026) | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 30.4% in Q2 and 36.2% YTD compared to 2025. This reflects the anticipated reduction in reimbursed costs under the BARDA contract following FDA authorization, as the scope narrowed to specific development projects with cost-share provisions.
- Increased Operating Expenses: Operating expenses rose 23.2% in Q2 and 11.3% YTD. Selling and marketing expenses increased 92.1% in Q2 due to pre-commercialization activities. General and administrative expenses increased due to higher stock-based compensation.
- Debt Financing: On June 18, 2026, the company drew down a second tranche of $6.5 million under its Avenue Capital Financing, bringing total debt to approximately $14.9 million. The interest-only period was extended to 24 months.
- Warrant Liability Volatility: The change in fair value of warrant liabilities resulted in a non-cash gain of $0.71 million in Q2 2026, compared to a loss of $5.45 million in Q2 2025, significantly impacting the net loss.
Guidance, Outlook, and Risks
- Commercialization: The company expects to generate its first commercial sales in the U.S. by the end of 2026 and begin commercialization in the U.K. in 2026.
- Liquidity: Management believes cash, the BARDA contract (with $31.7 million accelerated funding received in March 2026), and the Yorkville SEPA provide sufficient working capital for at least one year beyond the filing date.
- Material Weakness: The company identified a material weakness in internal controls over financial reporting related to the financial statement close process, account reconciliations, and transaction processing. A new CFO has been appointed, and remediation efforts are underway.
- Risks: Key risks include dependence on government contracts (BARDA accounted for 93% of Q2 revenue), supply chain disruptions, and the need for additional capital if commercialization is delayed.
Investor Verification Checklist
- Commercial Timeline: Verify the actual launch date of commercial sales in the U.S. and U.K. against the "end of 2026" expectation.
- BARDA Contract Terms: Review the specific cost-share provisions and remaining option values ($63.4 million) under the BARDA contract to assess future revenue stability.
- Debt Covenants: Examine the Avenue Financing agreement for specific covenants and the impact of the $15 million total facility on future liquidity.
- Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness in internal controls to ensure future reporting reliability.
- Warrant Liability Exposure: Assess the sensitivity of the $11.78 million warrant liability to stock price fluctuations, as this creates significant non-cash volatility in net income.